Disseminated on behalf of MindBio Therapeutics Corp., may include paid advertisements.
Investment Considerations
- MindBio has developed a first-mover position in voice-based intoxication detection, supported by proprietary algorithms and a large clinical dataset.
- The company’s dual-channel strategy spans both consumer applications and enterprise deployments, providing multiple pathways to commercialization.
- Its platform offers a non-invasive, scalable alternative to traditional testing methods, addressing limitations related to cost, speed, and accessibility.
- The business model combines hardware deployment with recurring software revenue, supporting a scalable SaaS-driven approach.
- The company is targeting multiple large and growing markets, including workplace safety, telehealth, and digital health, which collectively represent significant expansion opportunities.
MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is a biotechnology company developing and commercializing artificial intelligence-powered health prediction technologies that use the human voice as a diagnostic input. The company’s platform is centered on acoustic biomarker analysis, transforming speech into measurable physiological insights that can be used to detect drug and alcohol intoxication and support broader health monitoring applications. By leveraging voice as a non-invasive data source, MindBio is advancing a scalable approach to real-time diagnostics.
The company’s technology is built on clinical trials and large-scale data analysis, with predictive models trained on more than 50 million data points and supported by multiple studies demonstrating high levels of accuracy in intoxication detection. This foundation enables both consumer-facing and enterprise-grade applications, positioning MindBio to address use cases ranging from personal awareness tools to workforce safety and regulatory compliance in high-risk industries.
MindBio is advancing toward commercialization through a dual-channel strategy that includes a launched consumer application and enterprise solutions in development for large-scale deployment. Recent company activity highlights a transition toward field implementation, particularly within the mining sector, alongside expansion into industries such as aviation and construction. The platform is also being developed for broader applications in telehealth and remote monitoring.
The company is headquartered in Melbourne, Australia.
Products and Platform
Booze AI (Consumer Application)
MindBio’s Booze AI application enables users to estimate blood alcohol concentration using voice input via a smartphone or web-based interface. The platform combines speech analysis with behavioral tasks to provide real-time insights into intoxication levels and performance impairment, supporting awareness and harm prevention through accessible, non-invasive testing.
Enterprise Solutions
MindBio is developing enterprise-grade solutions for safety-critical industries such as mining, aviation, and construction, where impairment detection is essential. These solutions are designed for scalable, real-time screening of drug and alcohol intoxication, addressing limitations of traditional methods that are invasive, time-consuming, and operationally restrictive at scale. Recent developments include expansion into South America, deployment of engineering teams, and preparation for initial field testing of enterprise solutions in mining environments.
Core Technology and Platform
The company’s platform is built on proprietary AI models trained on more than 50 million data points and over 140 acoustic parameters extracted from human speech. This acoustic biomarker engine enables rapid, non-invasive detection of physiological and cognitive changes, delivering results in seconds with demonstrated accuracy exceeding 85% for BAC prediction and approximately 88% for intoxication classification, as validated through controlled studies and real-world testing.
To support enterprise adoption, MindBio is developing an integrated Edge AI hardware-software platform, including voice-initiated, touchless kiosk-based systems for on-site deployment with real-time, on-device analysis and audit-ready data capture for compliance. The platform is designed to support both hardware sales and recurring software revenue, while also expanding into adjacent applications such as telehealth, remote monitoring, and multi-substance detection using the same underlying voice analysis technology.
Market Opportunity
MindBio is targeting a total addressable market of approximately $47 billion in workplace safety and substance testing, driven by regulatory requirements across industries such as mining, aviation, construction, and transportation. The global workplace drug testing market is estimated at $15.4 billion, reflecting continued demand for solutions that can improve efficiency, scalability, and compliance in safety-critical environments.
The company also operates within broader high-growth markets, including telehealth and remote monitoring, projected to reach $285 billion, and consumer health applications estimated at $18.2 billion. These opportunities are supported by larger trends in digital health and alcohol-related harm, including a $547 billion digital health market and an estimated $1.6 trillion global cost associated with alcohol-related harm, reinforcing demand for scalable, non-invasive diagnostic technologies.
Leadership Team
Justin Hanka, Founder & CEO, brings a background in merchant and investment banking, with multiple successful exits and a focus on advancing technologies that have a meaningful impact on global health outcomes.
Gavin Upiter, Non-Executive Chairman, brings more than 25 years of experience in the pharmaceutical industry, including founding Generic Health, which was later sold to Lupin.
John Dinan, CFO, brings experience as a public and private company chief financial officer, with expertise in private equity and mergers and acquisitions, as well as a background as an Olympic sprinter and record holder.
Paul Lopez, Chief Engineer, brings more than 20 years of experience working with leading technology companies, with expertise in artificial intelligence and software design, and leads the company’s global engineering team.
